Key result
Aliskiren lowers BP dose-dependently up to 300 mg daily, comparable to other antihypertensive classes.
Aliskiren is a clinically effective direct renin inhibitor that provides dose-dependent blood pressure reduction in patients with hypertension, with additive effects when combined with diuretics or ARBs.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Renin inhibition has long been considered a desirable treatment approach and these recent study results provide evidence that aliskiren provides well-tolerated, 24-hour blood pressure control. Further studies will evaluate whether aliskiren has the potential to provide end-organ protection.”
“Aliskiren works well when given as monotherapy, but we have found that it also provides significant additional blood pressure reductions when combined with HCTZ treatment.”
“In a field were every millimeter does matter, this drug seems like a promising new addition to the arsenal in the fight against hypertension. However, unlike our abundant knowledge of the additional cardiac and renoprotective effects of ACE-I and ARBs, no long-term outcome data is available yet for aliskiren.”
May support renin inhibition for BP lowering in hypertension; leaves open outcome benefits in larger trials.
Gradman et al. (2008) conducted a review in Hypertension. Aliskiren was evaluated. Aliskiren, a direct renin inhibitor, produces dose-dependent blood pressure reduction up to 300 mg daily in patients with hypertension, with efficacy comparable to other antihypertensive classes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: